Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells $483,650.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $96.73, for a total value of $483,650.00. Following the sale, the chief executive officer directly owned 2,287,500 shares of the company’s stock, valued at $221,269,875. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

iRadimed Stock Performance

NASDAQ:IRMD opened at $97.04 on Thursday. The stock’s 50 day moving average price is $87.82 and its 200 day moving average price is $73.73. iRadimed Corporation has a 52 week low of $47.48 and a 52 week high of $98.44. The company has a market capitalization of $1.23 billion, a P/E ratio of 58.81 and a beta of 1.06.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The firm had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, sell-side analysts forecast that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The business also recently announced a special dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th will be issued a dividend of $0.50 per share. The ex-dividend date is Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is 41.21%.

Hedge Funds Weigh In On iRadimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC boosted its holdings in iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 211 shares during the period. Quarry LP acquired a new position in shares of iRadimed during the third quarter valued at about $40,000. Tower Research Capital LLC TRC lifted its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares during the period. State of Alaska Department of Revenue acquired a new stake in iRadimed during the third quarter worth about $47,000. Finally, Spire Wealth Management bought a new position in iRadimed during the second quarter valued at about $60,000. Institutional investors own 92.34% of the company’s stock.

Wall Street Analyst Weigh In

IRMD has been the topic of a number of recent analyst reports. Roth Capital set a $90.00 price objective on iRadimed in a research note on Friday, October 31st. Lake Street Capital reiterated a “buy” rating and set a $100.00 price target on shares of iRadimed in a report on Monday, November 3rd. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday. Finally, Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $87.33.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.